trial · primary record
Atorvastatin 80 mg/day
Arrhythmogenic Cardiomyopathy
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 102 |
| Primary completion | 2026-12-30 |
| Primary endpoint | Efficacy of Atorvastatin in avoiding functional right ventricular deterioration |
| Registry ID | NCT06922994 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:33:12.021Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06922994
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.